Neurol. praxi. 2017;18(4):271-273 | DOI: 10.36290/neu.2019.034
Treatment with the monoclonal antibody alemtuzumab: effect on the manifestation of thyroid disorders
- Klinika nukleární medicíny a endokrinologie 2. LF UK a FN Motol, Praha
Alemtuzumab is a humanized monoclonal antibody directed against the CD52 surface marker that is expressed on the cell surfaceof immune cells. This antibody induces a rapid and long-lasting removal of lymphocyte populations from the circulation. Treatmentwith alemtuzumab is particularly used in patients with multiple sclerosis (MS). In those with the relapsing-remitting form ofMS, it significantly reduces the risk of relapse and improves their health condition. This antibody is also used in the treatment ofpatients with chronic lymphocytic leukaemia and in kidney transplantation. Alemtuzumab has an effect on immune functions. Inpatients treated with alemtuzumab, there is an increased rate of autoimmune diseases and a mild increase in infections resultingfrom the treatment. The most frequent autoimmune damage associated with alemtuzumab treatment is thyroid disease. Lessfrequent is the occurrence of idiopathic thrombocytopenic purpura and autoimmune glomerulonephritis.
Keywords: thyroid gland, autoimmune disease, alemtuzumab, hypothyroidism, hyperthyroidism
Received: May 6, 2019; Accepted: May 6, 2019; Prepublished online: May 6, 2019; Published: October 1, 2017 Show citation
References
- Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000; 123(Pt 6): 1102-1111.
Go to original source... - Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon ?-1a at 5-year follow-up of CAMMS223 Clinical Trial. 2012; Neurology 78(14): 1069-1078. Go to original source...
Go to PubMed... - Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014; 99(1): 80-89. Go to original source...
- Heinzlef O, Alamowitch S, Sazdovitch V, Chillet P, Joutel A, Tournier-Lasserve E, Roullet E. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand. 2000; 101(1): 36-40. Go to original source... Go to PubMed...
- Jones LJ, Coles AJ. Mode of action and clinical studies with alemtuzumab Experimental Neurology, 2014; 262(A): 37-43. Go to original source...
- Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab Clinical Immunology, 2012; 142(1): 25-30. Go to original source...
- Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC. Graves' disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens). 2015; 14(1): 148-53. Go to PubMed...
- Willis MD, Robertson NP. Alemtuzumab for multiple sclerosis. Curr Neurol Neurosci Rep. 2016; 16(9): 84. Go to original source... Go to PubMed...